

10. Concurrent benzodiazepine use in older

by Xiao Mei Zhong

Submission date: 03-Apr-2023 12:09PM (UTC+0800)

Submission ID: 2054232277

File name: 10_Concurrent_benzodiazepine_use_in_older.pdf (126.19K)

Word count: 4709

Character count: 26866

Concurrent benzodiazepine use in older adults treated with antidepressants in Asia

Xiao-Mei Zhong,^{1,2#} Fei Wang,^{2#} Qinge Zhang,^{3#} Gabor S. Ungvari,^{4,5} Chee H. Ng,⁶ Helen F. K. Chiu,⁷ Tian-Mei Si,⁸ Kang Sim,⁹ Ajit Avasthi,¹⁰ Sandeep Grover,¹⁰ Mian-Yoon Chong,¹¹ Kok-Yoon Chee,¹² Shigenobu Kanba,¹³ Min-Soo Lee,¹⁴ Shu-Yu Yang,¹⁵ Pichet Udomratn,¹⁶ Roy A. Kallivayalil,¹⁷ Andi J. Tanra,¹⁸ Margarita M. Maramis,¹⁹ Winston W. Shen,²⁰ Norman Sartorius,²¹ Rathi Mahendran,²² Chay-Hoon Tan,²³ Naotaka Shinfuku²⁴ and Yu-Tao Xiang²

¹Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Hui Hospital), Guangzhou, China

²Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China

³The National Clinical Research Center for Mental Disorders, China & Center of Depression, Beijing Institute for Brain Disorders & Mood Disorders Center, Beijing Anding Hospital, Capital Medical University, Beijing, China

⁴The University of Notre Dame Australia/Marian Centre, Perth, Australia

⁵Graylands Hospital, Perth, Australia

⁶Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia

⁷Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China

⁸Peking University Institute of Mental Health (the sixth hospital) & National Clinical Research Center for Mental Disorders & the Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China

⁹Institute of Mental Health, Buangkok View, Buangkok Green Medical Park, Singapore

¹⁰Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

¹¹Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital-Kaohsiung Medical Center and School of Medicine, Chang Gung University, Taiwan

¹²Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia

¹³Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan

¹⁴Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea

¹⁵Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan

¹⁶Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand

¹⁷Department of Psychiatry, Pushpagiri Institute of Medical Sciences, Thiruvalla, India

¹⁸Department of Psychiatry, Hasanuddin University Faculty of Medicine, Makassar, Sulawesi Selatan, Indonesia

¹⁹Dr. Soetomo Hospital – Faculty of Medicine, Airlangga University, Jember Timur, Indonesia

²⁰Departments of Psychiatry, TMU-Wan Fang Medical Center and School of Medicine, Taipei Medical University, Taiwan

²¹Association for the Improvement of Mental Health Programmes, Geneva, Switzerland

²²Department of Psychological Medicine, National University of Singapore, Singapore

²³Department of Pharmacology, National University of Singapore, Singapore

²⁴International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan

ABSTRACT

Background: Little is known about the combined use of benzodiazepines and antidepressants in older psychiatric patients. This study examined the prescription pattern of concurrent benzodiazepines in older adults treated with antidepressants in Asia, and explored its demographic and clinical correlates.

Methods: The data of 955 older adults with any type of psychiatric disorders were extracted from the database of the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) project. Demographic and clinical characteristics were recorded using a standardized protocol and data collection procedure. Both univariate and multiple logistic regression analyses were performed.

Results: The proportion of benzodiazepine and antidepressant combination in this cohort was 44.3%. Multiple logistic regression analysis revealed that higher doses of antidepressants, younger age (<65 years), inpatients, public hospital, major comorbid medical conditions, antidepressant types, and country/territory were significantly associated with more frequent co-prescription of benzodiazepines and antidepressants.

Correspondence should be addressed to: Dr Yu-Tao Xiang, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau SAR, 3/F, Building E12, China. Phone: +853-8822-4223; Fax: +853-2288-2314. Email: xyutly@gmail.com. Received 25 May 2017; revision requested 18 Jul 2017; revised version received 23 Oct 2017; accepted 24 Oct 2017.

These authors contributed equally to this work.

Conclusions: Nearly, half of the older adults treated with antidepressants in Asia are prescribed concurrent benzodiazepines. Given the potentially adverse effects of benzodiazepines, the rationale of benzodiazepines and antidepressants co-prescription needs to be revisited.

Key words: antidepressant, benzodiazepines, older adults, Asia

Introduction

Psychiatric disorders are common in older adults. For example, the prevalence of depression was 5.7% in Singapore (Kua, 1992) and 5.9% in Taiwan (Chong *et al.*, 2001). A survey conducted in China found that the prevalence of insomnia was 7.6% in older adults (Dai *et al.*, 2013). Due to the high rates of both conditions, benzodiazepines and antidepressants are often prescribed for this population. For example, 10% older adults with depression in the USA received benzodiazepines and antidepressants simultaneously between 2001 and 2014 (Bushnell *et al.*, 2017).

In older adults, antidepressant use has increased in the past decades (Soudry *et al.*, 2008; Parabiaghi *et al.*, 2011; Aarts *et al.*, 2014). In one survey, 38% of older adults living in nursing homes received at least one antidepressant (Manthey *et al.*, 2011). Benzodiazepines are commonly used in older adults primarily for sleep problems and anxiety (Smith and Tett, 2009), but chronic use of benzodiazepines is problematic because of common side effects, such as dependence, excessive sedation, falls, and cognitive impairment (Volz *et al.*, 2007). In Japan, 20–50% of older persons with psychiatric patients are prescribed benzodiazepines (Uchida *et al.*, 2009). Another survey in Asia found that 20.7% of older patients with schizophrenia received benzodiazepines (Xiang *et al.*, 2012).

Compared to younger people, older adults are more likely to have poorer general health and more frequent medication-induced adverse events (Meyers and Jeste, 2010). The latter is related to pharmacokinetic changes with advanced age affecting drug absorption, metabolism and excretion (Masand, 2000). In addition, older adults have age-related changes in pharmacodynamic response to benzodiazepines (Kruse, 1990), which increases the risk of adverse effects. As a consequence, prescription of benzodiazepines for older adults may often be harmful (Manthey *et al.*, 2011).

Regular cross-sectional surveys of prescription patterns are an efficient and quick method to assess the appropriateness of pharmacotherapy (Ungvari *et al.*, 1997). Several surveys have examined the combined use of benzodiazepines and antidepressants for psychiatric disorders, with the percentage ranging from 20.5% to 57% (van Dijk *et al.*, 2002; Leggett *et al.*, 2015; Fulone *et al.*,

2016; Bushnell *et al.*, 2017). However, very little is known about the co-prescription of these two groups of medications in Asian older psychiatric patients (Xiang *et al.*, 2014a).

This study examined the prescribing patterns of concurrent benzodiazepines and antidepressants in older psychiatric patients in Asia, and explored their associated demographic and clinical features.

Methods

Study sample and sites

This study was a secondary analysis of the database of the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) project, which is a pharmaco-epidemiological study on antidepressant prescription patterns in psychiatric patients at 42 hospitals in 10 Asian countries/territories, including China, Hong Kong, Japan, Korea, Singapore, Taiwan, India, Malaysia, Thailand, and Indonesia. Patients who received antidepressants on the day of the survey were consecutively included in the REAP-AD study. Data collection followed the same standardized protocol and collection procedure at all study sites. Due to different local conventions, the cut-off age for older adults across the participating countries/territories ranged from 50 to 65 years. To ensure a homogeneous sample for the analysis, patients aged ≥ 50 years in the REAP-AD project were defined as “older adults.” The same age cut-off was also used in other studies (Dassori *et al.*, 2011; Xiang *et al.*, 2014a) and in a World Health Organization report (WHO, 2001).

Assessments

Basic demographic and clinical characteristics were collected by a review of medical records verified by members of the research team at each site. Benzodiazepines were listed according to the World Health Organization Anatomical Therapeutic Chemical (ATC) classification system (WHO Collaborating Centre for Drug Statistic Methodology, 2002). Doses of antidepressants were converted into imipramine equivalent (IMIEq) mg/d doses (Rajaratnam *et al.*, 2016).

The study protocol was approved by the clinical research and ethics committee at each study site. Because the survey was anonymous and posed no

risk to patients, informed consent was waived at some study sites according to the requirements of the local ethics committee (Shinfuku and Tan, 2008), if only medical records was reviewed. All patients receiving interview provided consent according to the requirements of the ethics committee in the respective study sites.

12

Data analysis

Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 22.0 (IBM SPSS, Chicago, IL, USA). Comparisons of the demographic and clinical characteristics between patients on benzodiazepines plus antidepressants and those on antidepressants only were conducted using χ^2 test, independent sample *t*-test, and Mann–Whitney *U*-test, as appropriate. Multiple logistic regression analysis with the “Enter” method was used to identify the demographic and clinical variables independently influencing benzodiazepines and antidepressants combination. The variables showing significant group difference in univariate analysis were independent variables, while benzodiazepines and antidepressants combination was the dependent variable. The level of significance was set at 0.05 (two-tailed).

Results

Of 955 patients treated with antidepressants included in the study, 44.3% were prescribed a combination of benzodiazepines and antidepressants (Table 1). Table 2 presents the basic demographic and clinical characteristics of the whole sample and separately for the combined benzodiazepine/antidepressant group. Younger age, higher dose of antidepressants, being treated in psychiatric hospitals, inpatient treatment, country/territory, major comorbid medical conditions, antidepressant type, and use of second-generation antipsychotics (SGAs) were significantly associated with co-prescription of benzodiazepines and antidepressants. Table 3 shows the independent demographic and clinical correlates of the combination treatment: higher doses of antidepressants, younger age (<65 years), inpatients, public hospital, major comorbid medical conditions, antidepressant types, and country/territory were significantly associated with more frequent co-prescription of benzodiazepines and antidepressants. The most commonly prescribed benzodiazepines were lorazepam (27%) and clonazepam (24%). The most common physical comorbidities were diabetes mellitus (27.5%), followed by cerebrovascular diseases (11.4%) and peptic ulcer (5.7%).

Discussion

This was the first large-scale, international survey of concurrent prescription of benzodiazepines and antidepressants in older adults. The proportion of combination treatment was 44.3% in Asia, which is lower than the figure (52%) in patients with major depression (mean age: 52.1 years) in Brazil (Fulone *et al.*, 2016), but higher than the 20.5% found in older veterans with depression (mean age: 64.9 years) in the USA (Leggett *et al.*, 2015).

The common use of antidepressants together with benzodiazepines could be due to several reasons. Depression with comorbid anxiety and insomnia is common in older adults (Biderman *et al.*, 2002; Johnson *et al.*, 2006; Neckelmann *et al.*, 2007), which justifies this practice. In addition, concerns about benzodiazepine withdrawal may contribute to the long-term use of these medications (Xiang *et al.*, 2012). In general, the combination of psychotropic medications with different pharmaceutical properties is common medical practice in Asian countries (Binder *et al.*, 1987). There was considerable variation in the combination treatment across different countries/territories that ranged from 26.7% in Korea to 59.7% in Japan. The variability in prescribing could be due to different insurance coverage, healthcare policies, psychopharmacological traditions, and medication costs (Xiang *et al.*, 2013).

In this study, the combined use of benzodiazepines and antidepressants was associated with younger age, inpatients, and being treated in public hospitals. These associations are probably related to the severity of psychiatric symptoms. Such combinations are usually prescribed for severe symptoms of depression, anxiety, and insomnia (Millan, 2014; Xiang *et al.*, 2014a). Relatively younger patients are more prone to present with severe psychiatric symptoms that are more likely to necessitate hospitalization in public psychiatric wards (White *et al.*, 1995; Zhang *et al.*, 2004; Xiang *et al.*, 2014a).

Insomnia, anxiety, and depressive symptoms are common in older adults with major medical conditions (Manthey *et al.*, 2011; Xiang *et al.*, 2014b), which could explain the high rate of polypharmacy. Antidepressant types and countries/territories were also associated with co-prescription of benzodiazepines and antidepressants. Socio-cultural factors, prescription traditions, access to psychotropic drugs, insurance coverage, costs and healthcare policies might contribute to the combined prescription (Xiang *et al.*, 2007). Higher antidepressant doses were significantly associated with more frequent combined treatment, but the minor difference

Table 1. Distribution of patients by study sites

COUNTRY/ TERRITORY	CHINA (N = 158)		HONG KONG (N = 39)		JAPAN (N = 119)		KOREA (N = 150)		SINGAPORE (N = 48)		TAIWAN (N = 109)		INDIA (N = 63)		MALAYSIA (N = 67)		THAILAND (N = 128)		INDONESIA (N = 74)		OVERALL (N = 955)	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Receiving BZDs	64	40.5	19	48.7	71	59.7	40	26.7	16	33.3	76	69.7	18	28.6	31	46.3	50	39.1	38	51.4	423	44.3
Receiving TCAs	6	3.8	3	7.7	15	12.6	18	12	1	2.1	8	7.3	7	11.1	1	1.5	33	25.8	7	9.5	99	10.4
Receiving tricyclics	0	0	0	0	7	5.9	0	0	0	0	0	0	0	0	1	1.5	19	14.8	0	0	27	2.8
Receiving SSRIs	103	65.2	21	53.8	52	43.7	101	67.3	30	62.5	57	52.3	44	69.8	47	70.1	71	55.5	67	90.5	593	62.1
Receiving SNRIs	42	26.6	7	17.9	24	20.2	35	23.3	3	6.3	22	20.2	10	15.9	4	6	8	6.3	0	0	155	16.2
Receiving NaSSAs	31	19.6	6	15.4	40	33.6	36	24	12	25	11	10.1	6	9.5	13	19.4	8	6.3	0	0	163	17.1
Receiving other drugs	12	7.6	6	15.4	16	13.4	39	26	5	10.4	23	21.1	2	3.2	2	3	22	17.2	0	0	127	13.3

Notes: BZD = benzodiazepines; TCA = tricyclic antidepressants; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin/norepinephrine reuptake inhibitor; NaSSA = noradrenergic and specific serotonergic antidepressant.

Table 2. Basic demographic and clinical characteristics of the study sample

	TOTAL SAMPLE (N = 955)		NO BZDs (N = 532)		ON BZDs (N = 423)		STATISTICS		
	MEAN	SD	MEAN	SD	MEAN	SD	T/Z	DF	p
Age (years)	62.6	9.5	63.6	9.9	61.2	8.8	3.9	953	<0.001
AD dose, IMEq (mg/d)	131.2	112.5	123.5	107.8	140.9	117.4	-3.6	-	<0.001
	N	%	N	%	N	%	χ^2	df	p
Age (years)							11.1	1	0.001
50-64	615	64.4	318	59.8	297	70.2			
65 and older	340	35.6	214	40.2	126	29.8			
Female	580	60.7	325	61.1	255	60.3	0.06	1	0.80
Psychiatric hospital	351	36.8	181	34.0	170	40.2	3.8	1	0.049
Inpatients	233	24.4	96	18.0	137	32.4	26.2	1	<0.001
Public hospital	687	71.9	363	68.2	324	76.6	8.1	1	0.004
Country/territory							71.7	9	<0.001
Income group							4.3	2	0.112
High income	465	48.7	243	45.7	222	52.5			
Upper middle income	353	37.0	208	39.1	145	34.3			
Lower middle income	137	14.3	81	15.2	56	13.2			
Major medical conditions	421	44.1	213	40.0	208	49.2	7.9	1	0.005
Use of antidepressants									
TCAs	99	10.4	57	10.7	42	9.9	0.1	1	0.69
Tetracyclics	27	2.8	14	2.6	13	3.1	0.1	1	0.68
SSRIs	593	62.1	338	63.5	255	60.3	1.0	1	0.30
SNRIs	155	16.2	90	16.9	65	15.4	0.4	1	0.51
NaSSAs	163	17.1	89	16.7	74	17.5	0.09	1	0.75
Other antidepressants	127	13.3	59	11.1	68	16.1	5.0	1	0.02
Use of FGAs	83	8.7	41	7.7	42	9.9	1.4	1	0.22
Use of SGAs	238	24.9	117	22.0	121	28.6	5.5		0.019
Use of MS	63	6.6	28	5.3	35	8.3	3.4		0.06
Principal psychiatric diagnosis							0.4	3	0.92
Mood disorders	671	70.3	374	70.3	297	70.2			
Anxiety disorders	130	13.6	72	13.5	58	13.7			
Schizophrenia	79	8.3	42	7.9	37	8.7			
Other diagnoses	75	7.9	44	8.3	31	7.3			

Bolded values: <0.05; AD = antidepressants; BZD = benzodiazepines; TCA = tricyclic antidepressants; NaSSA = noradrenergic and specific serotonergic antidepressant; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin/norepinephrine reuptake inhibitor; IMI-eq = imipramine-equivalent; FGA = first-generation antipsychotic; SGA = second-generation antipsychotic; MS = mood stabilizer.

(OR: 1.002) is not clinically relevant in clinical practice.

There are several limitations to this study. First, due to the cross-sectional design, the causality between benzodiazepines and antidepressants co-prescription and variables, such as change of psychotropic medications, could not be examined. Second, the sample size was very small in some countries/territories, therefore, their associations with benzodiazepine prescription could not be examined by countries/territories. The whole sample size was also relatively small compared to the huge number of patient population in the ten Asian countries/territories, which constitutes a probable ascertainment bias. Third, the efficacy and side effects of the benzodiazepine-

antidepressant combination were not measured. Fourth, relevant contributing factors, such as treatment costs and health insurance policy could not be examined. Fifth, due to logistic reasons, the presence of depressive and anxiety symptoms and insomnia were not assessed using standardized tools. Finally, only patients who received antidepressants on the day of the survey were included in the REAP-AD project. The sample in this study could not represent all patients attending medical treatment in the participating countries/territories.

In conclusion, nearly half of older adults treated with antidepressants in Asia were prescribed concurrent benzodiazepines. Considering the age-related risk of drug-induced adverse effects in

Table 3. Independent demographic and clinical correlates of the benzodiazepines and antidepressants combination

VARIABLES	p VALUE	ODDS	
		RATIO	95% CI
AD dose, IMI-eq (mg/d)	0.010	1.002	1.0–1.003
65 years and older	0.001	0.591	0.4–0.8
Psychiatric hospital	0.74	0.940	0.6–1.3
Outpatients	0.001	0.544	0.3–0.7
Public hospitals	0.003	2.077	1.2–3.3
Use of SGAs	0.74	0.945	0.6–1.3
Major medical conditions	0.03	1.380	1.03–1.8
Use of other antidepressants	0.016	1.6	1.1–2.5
Country/territory			
China	<0.001	1	0
Indonesia	0.007	2.273	1.2–4.1
Hong Kong	0.45	1.321	0.6–2.7
Japan	<0.001	3.206	1.8–5.6
South Korea	0.86	1.058	0.5–2.0
Singapore	0.46	0.766	0.3–1.5
Taiwan	<0.001	5.837	3.1–10.9
India	0.92	0.968	0.4–1.9
Malaysia	0.18	1.551	0.8–2.9
Thailand	0.58	1.160	0.6–1.9

Bolded values: <0.05; participating country/territory has been controlled for as a covariate. AD = antidepressants; IMI-eq = imipramine-equivalent; SGA = second-generation antipsychotic.

this population, the rationale of benzodiazepines and antidepressants co-prescription needs to be revisited.

Conflict of interest

All authors declare no conflicts of interest concerning this article.

Description of authors' roles

Study design: Naotaka Shinfuku, Norman Sartorius, Helen F. K. Chiu, Tian-Mei Si, Mian-Yoon Chong, Kang Sim, and Chay-Hoon Tan. **Data collection, analysis, and interpretation:** Xiao-Mei Zhong, Fei Wang, Qinge Zhang, Yu-Tao Xiang, Kok-Yoon Chee, Ajit Avasthi, Sandeep Grover, Shigenobu Kanba, Min-Soo Lee, Shu-Yu Yang, and Andi J. Tanra. **Drafting of the manuscript:** Xiao-Mei Zhong, Fei Wang, Qinge Zhang, Yu-Tao Xiang, Gabor S. Ungvari, and Chee H. Ng. **Critical revision of the manuscript:** Ajit Avasthi, Sandeep Grover, Kok-Yoon Chee, Shigenobu Kanba, Min-Soo Lee, Pichet Udomratn, Roy A. Kallivayalil, Andi J. Tanra, Margarita M. Maramis, Winston W. Shen, and Rathi Mahendran. **Approval of the final version for publication:** all co-authors.

Acknowledgments

This study was supported by the Taipei City Hospital (10201-62-077), Taipei, Taiwan and the University of Macau (SRG2014-00019-FHS; MYRG2015-00230-FHS; MYRG2016-00005-FHS). The authors thank all clinicians involved in the REAP-AD project.

References

- Aarts, N., Noordam, R., Hofman, A., Tiemeier, H., Stricker, B. H. and Visser, L. E. (2014). Utilization patterns of antidepressants between 1991 and 2011 in a population-based cohort of middle-aged and elderly. *European Psychiatry*, 29, 365–370.
- Biderman, A., Cwikel, J., Fried, A. V. and Galinsky, D. (2002). Depression and falls among community dwelling elderly people: a search for common risk factors. *Journal of Epidemiology and Community Health*, 56, 631–636.
- Binder, R. L., Kazamatsuri, H., Nishimura, T. and McNeil, D. E. (1987). Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. *American Journal of Psychiatry*, 144, 1494–1496.
- Bushnell, G. A., Stürmer, T., Gaynes, B. N., Pate, V. and Miller, M. (2017). Simultaneous Antidepressant and Benzodiazepine new use and subsequent long-term Benzodiazepine use in adults with depression, United States, 2001–2014. *JAMA Psychiatry*, 74, 747–755.
- Chong, M. Y. *et al.* (2001). Community study of depression in old age in Taiwan: prevalence, life events and socio-demographic correlates. *British Journal of Psychiatry*, 178, 29–35.
- Dai, J. *et al.* (2013). The prevalence of insomnia and its socio-demographic and clinical correlates in older adults in rural China: a pilot study. *Aging Ment Health*, 17, 761–765.
- Dassori, A. M., Copeland, L. A., Zeber, J. E. and Miller, A. L. (2011). Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. *Psychiatric services*, 62, 47–53.
- Fulone, I., Silva, M. T. and Lopes, L. C. (2016). Factors associated with the combined use of antidepressants and Benzodiazepines in major depression: a case-control study. *Basic & clinical pharmacology & toxicology*, 119, 273–277.
- Johnson, E. O., Roth, T. and Breslau, N. (2006). The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. *Journal of Psychiatric Research*, 40, 700–708.
- Kruse, W. H. H. (1990). Problems and Pitfalls in the Use of Benzodiazepines in the Elderly. *Drug Safety*, 5, 328–344.
- Kua, E. H. (1992). A community study of mental disorders in elderly Singaporean Chinese using the GMS-AGECAT package. *Australian and New Zealand Journal of Psychiatry*, 26, 502–506.
- Leggett, A., Kavanagh, J., Zivin, K., Chiang, C., Kim, H. M. and Kales, H. C. (2015). The association between Benzodiazepine use and depression outcomes in older veterans. *Journal of geriatric psychiatry and neurology*, 28, 281–287.

- Manthey, L. et al.** (2011). Correlates of (inappropriate) benzodiazepine use: the Netherlands study of depression and anxiety (NESDA). *British Journal of Clinical Pharmacology*, 71, 263–272.
- Masand, P. S.** (2000). Side effects of antipsychotics in the elderly. *Journal of Clinical Psychiatry*, 61(Suppl. 8), S43–S49.
- Meyers, B. S. and Jeste, D. V.** (2010). Geriatric psychopharmacology: evolution of a discipline. *Journal of Clinical Psychiatry*, 71, 1416–1424.
- Millan, M. J.** (2014). On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. *International Journal of Neuropsychopharmacology*, 17, 1009–1037.
- Neckelmann, D., Mykletun, A. and Dahl, A. A.** (2007). Chronic insomnia as a risk factor for developing anxiety and depression. *Sleep*, 30, 873–880.
- Parabiaghi, A. et al.** (2011). Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. *European Journal of Clinical Pharmacology*, 67, 1077–1083.
- Rajaratnam, K. et al.** (2016). Factors associated with antidepressant dosing in Asia: findings from the research on Asian psychotropic prescription study. *Journal of Clinical Psychopharmacology*, 36, 716–719.
- Shinfuku, N. and Tan, C. H.** (2008). Pharmacotherapy for schizophrenic inpatients in East Asia—changes and challenges. *International Review of Psychiatry*, 20, 460–468.
- Smith, A. J. and Tett, S. E.** (2009). How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003–6. *Drugs and Aging*, 26, 113–122.
- Soudry, A., Dufouil, C., Ritchie, K., Dartigues, J. F., Tzourio, C. and Alperovitch, A.** (2008). Factors associated with changes in antidepressant use in a community-dwelling elderly cohort: the three-city study. *European Journal of Clinical Pharmacology*, 64, 51–59.
- Uchida, H. et al.** (2009). Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. *Journal of Anxiety Disorders*, 23, 477–481.
- Ungvari, G. S., Chow, L. Y., Chiu, H. F., Ng, F. S. and Leung, T.** (1997). Modifying psychotropic drug prescription patterns: a follow-up survey. *Psychiatry and clinical neurosciences*, 51, 309–314.
- van Dijk, K. N., de Vries, C. S., ter Huurne, K., van den Berg, P. B., Brouwers, J. R. and de Jong-van den Berg, L. T.** (2002). Concomitant prescribing of benzodiazepines during antidepressant therapy in the elderly. *Journal of Clinical Epidemiology*, 55, 1049–1053.
- Volz, A., Khorsand, V., Gillies, D. and Leucht, S.** (2007). Benzodiazepines for schizophrenia. Cochrane Database Systematic Review, CD006391.
- White, C. L., Bateman, A., Fisher, W. H. and Geller, J. L.** (1995). Factors associated with admission to public and private hospitals from a psychiatric emergency screening site. *Psychiatric services*, 46, 467–472.
- WHO** (2001). *Information Needs for Research, Policy and Action on Ageing and Older Adults: A Report of the Follow-up Meeting to the 2000 Harare MDS Workshop*. Geneva: World Health Organization.
- WHO Collaborating Centre for Drug Statistic Methodology** (2002). *Guidelines for ATC Index with DDDs*. Oslo: WHO.
- Xiang, Y. T. et al.** (2012). Adjunctive mood stabilizer and Benzodiazepine use in older Asian Patients with Schizophrenia, 2001–2009. *Pharmacopsychiatry*, 45, 217–222.
- Xiang, Y. T. et al.** (2013). Adjunctive antidepressant prescriptions for hospitalized patients with schizophrenia in Asia (2001–2009). *Asia and Pacific Psychiatry*, 5, E81–E87.
- Xiang, Y. T. et al.** (2014a). Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001–2009). *International Journal of Geriatric Psychiatry*, 29, 359–366.
- Xiang, Y. T. et al.** (2014b). Insomnia in older adults with chronic obstructive pulmonary disease (COPD) in Hong Kong: a case-control study. *COPD*, 11, 319–324.
- Xiang, Y. T., Weng, Y. Z., Leung, C. M., Tang, W. K. and Ungvari, G. S.** (2007). Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. *Pharmacopsychiatry*, 40, 47–52.
- Zhang, W. H., Qiu, Z. F. and Zhang, L. J.** (2004). Several ethical problems on the closed ward of psychiatric department (in Chinese). *Chinese Journal of Medical Ethics*, 17, 1–2.

10. Concurrent benzodiazepine use in older

ORIGINALITY REPORT

18%

SIMILARITY INDEX

15%

INTERNET SOURCES

15%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

1	Qian Li, Yun-Ai Su, Yu-Tao Xiang, Liang Shu et al. "Electroconvulsive Therapy in Schizophrenia in China", The Journal of ECT, 2017 Publication	1%
2	www.mdpi.com Internet Source	1%
3	www.tandfonline.com Internet Source	1%
4	www.cambridge.org Internet Source	1%
5	Fei Wang, Li - Rong Meng, Qing E. Zhang, Lu Li et al. "Sleep disturbance and its relationship with quality of life in older Chinese adults living in nursing homes", Perspectives in Psychiatric Care, 2019 Publication	1%
6	coek.info Internet Source	1%

7

Xiang, Ying-Qiang, Wei Zheng, Shi-Bin Wang, Xin-Hu Yang, Dong-Bin Cai, Chee H. Ng, Gabor S. Ungvari, Deanna L. Kelly, Wei-Ying Xu, and Yu-Tao Xiang. "Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials", *European Neuropsychopharmacology*, 2016.

Publication

1 %

8

www.ncbi.nlm.nih.gov

Internet Source

1 %

9

Wen-Wang Rao, Ji-Wen Zhang, Qian-Qian Zong, Feng-Rong An, Gabor S. Ungvari, Lloyd Balbuena, Fang-Yu Yang, Yu-Tao Xiang. "Prevalence of depressive symptoms in overweight and obese children and adolescents in mainland China: A meta-analysis of comparative studies and epidemiological surveys", *Journal of Affective Disorders*, 2019

Publication

<1 %

10

Yun Chen, Ling Zhang, Li Yue, Qingjing Liu, William Montgomery, Lihua Zhi, Wanqi Wang. "Medication use patterns, health care resource utilization, and economic burden for patients with major depressive disorder in Beijing, People's Republic of China", *Neuropsychiatric Disease and Treatment*, 2016

<1 %

11	pureadmin.qub.ac.uk Internet Source	<1 %
12	works.bepress.com Internet Source	<1 %
13	Li, Yan, Cai-Lan Hou, Xin-Rong Ma, Yu Zang, Fu-Jun Jia, Bao-Liang Zhong, Yong-Qiang Lin, Helen F.K. Chiu, Gabor S. Ungvari, Seth Himelhoch, Xiao-Lan Cao, Mei-Ying Cai, Kelly Y.C. Lai, and Yu-Tao Xiang. "Smoking and its associations with sociodemographic and clinical characteristics and quality of life in patients with schizophrenia treated in primary care in China", <i>General Hospital Psychiatry</i> , 2016. Publication	<1 %
14	www.karger.com Internet Source	<1 %
15	www.slideshare.net Internet Source	<1 %
16	Hasib Salah-Uddin. "Altered M1 Muscarinic Acetylcholine Receptor (CHRM1)-Gaq/11 Coupling in a Schizophrenia Endophenotype", <i>Neuropsychopharmacology</i> , 04/29/2009 Publication	<1 %
17	file.scirp.org Internet Source	<1 %

18

scholarbank.nus.edu.sg

Internet Source

<1 %

19

www.questia.com

Internet Source

<1 %

20

Naotaka Shinfuku. "Mental health services in Asia: International perspective and challenge for the coming years", *Psychiatry and Clinical Neurosciences*, 2002

Publication

<1 %

21

clinicaltrials.gov

Internet Source

<1 %

22

core-cms.prod.aop.cambridge.org

Internet Source

<1 %

23

ddd.uab.cat

Internet Source

<1 %

24

doaj.org

Internet Source

<1 %

25

McIntyre, R.S.. "Bipolar disorder and metabolic syndrome: An international perspective", *Journal of Affective Disorders*, 201011

Publication

<1 %

26

www.thefreelibrary.com

Internet Source

<1 %

27

Fei Wang, Qing-E Zhang, Ling Zhang, Chee H. Ng, Gabor S. Ungvari, Zhen Yuan, June Zhang, Ling Zhang, Yu-Tao Xiang. "Prevalence of major depressive disorder in older adults in China: a systematic review and meta-analysis", Journal of Affective Disorders, 2018

Publication

<1 %

28

Wei Zheng, Xin-Ni Luo, Hai-Yan Li, Xiao-Yin Ke, Qing Dai, Chan-Juan Zhang, Xiang-Yang Zhang, Yu-Ping Ning. "Regional differences in the risk of insomnia symptoms among patients from general hospital outpatient clinics", Neuropsychiatric Disease and Treatment, 2018

Publication

<1 %

29

Wu, T.H.. "Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors", Progress in Neuropsychopharmacology & Biological Psychiatry, 20081212

Publication

<1 %

30

Xiang, Y.T.. "Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China", Progress in Neuropsychopharmacology & Biological Psychiatry, 20070413

Publication

<1 %

31	<p>Xiang, Yu-Tao, Gang Wang, Chen Hu, Tong Guo, Gabor S. Ungvari, Amy M. Kilbourne, Kelly Y. C. Lai, Tian-Mei Si, Qi-Wen Zheng, Da-Fang Chen, Yi-Ru Fang, Zheng Lu, Hai-Chen Yang, Jian Hu, Zhi-Yu Chen, Yi Huang, Jing Sun, Xiao-Ping Wang, Hui-Chun Li, Jin-Bei Z.</p> <p>"Demographic and Clinical Features and Prescribing Patterns of Psychotropic Medications in Patients with the Melancholic Subtype of Major Depressive Disorder in China", PLoS ONE, 2012.</p> <p>Publication</p>	<1 %
32	<p>dspace.xmu.edu.cn</p> <p>Internet Source</p>	<1 %
33	<p>es.scribd.com</p> <p>Internet Source</p>	<1 %
34	<p>pdfs.semanticscholar.org</p> <p>Internet Source</p>	<1 %
35	<p>pure.rug.nl</p> <p>Internet Source</p>	<1 %
36	<p>vuir.vu.edu.au</p> <p>Internet Source</p>	<1 %
37	<p>www.jove.com</p> <p>Internet Source</p>	<1 %
38	<p>Norny Syafinaz Ab Rahman, Fatin Azzyati Pakururrazi, Che Suraya Zin, Helina Abd</p>	<1 %

Halim. "Trends and patterns of benzodiazepines prescription from 2014 to 2016: A retrospective cross-sectional study in an outpatient setting of tertiary hospital in Malaysia.", Research Square Platform LLC, 2022

Publication

39

ndl.ethernet.edu.et

Internet Source

<1 %

40

rcastoragev2.blob.core.windows.net

Internet Source

<1 %

41

Arun K. Tiwari. "Pharmacogenetics of anxiolytic drugs", Journal of Neural Transmission, 05/12/2009

Publication

<1 %

42

Breedlove, S. Marc. "Behavioral Neuroscience", Oxford University Press

Publication

<1 %

43

Yeung, Dannii Y., Sylvia Y.C. Kwok, and Annie Chung. "Institutional peer support mediates the impact of physical declines on depressive symptoms of nursing home residents", Journal of Advanced Nursing, 2013.

Publication

<1 %

44

kar.kent.ac.uk

Internet Source

<1 %

link.springer.com

45

Internet Source

<1 %

46

pure.manchester.ac.uk

Internet Source

<1 %

47

www.hongkongpa.com.hk

Internet Source

<1 %

48

Phern-Chern Tor, Tze Pin Ng, Kian-Hui Yong, Kang Sim et al. "Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008", The International Journal of Neuropsychopharmacology, 2011

Publication

<1 %

49

Kang Sim, Ross J Baldessarini. "Comparative studies of psychotropic drug use over the last seven decades: Gaps and goals in global ethnopsychopharmacology", European Neuropsychopharmacology, 2022

Publication

<1 %

Exclude quotes On

Exclude matches Off

Exclude bibliography On

10. Concurrent benzodiazepine use in older

GRADEMARK REPORT

FINAL GRADE

/100

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7
